Public filings / NAMS on Yahoo Finance (opens in a new tab)
NAMS: insider buying, 13F holders, analyst moves
Newamsterdam Pharma Company
A summary of public filings about Newamsterdam Pharma Company. For the latest insider history, price chart, analyst changes and activist filings, open the live lookup.
SEC Form 13F · Q2 2026
8 of our 100 managers hold NAMS
Combined reported value $885.4M.
Holders among our 100 managers: 2 in Q3 2023, 8 in Q2 2026.
| Manager | Value | % of portfolio | Change vs Q1 2026 |
|---|---|---|---|
| RA Capital | $323.7M | 2.81% | Unchanged |
| Deerfield Company | $144.5M | 1.51% | Unchanged |
| Viking Global Investors | $142.5M | 0.41% | Unchanged |
| Maverick Capital | $110.7M | 1.00% | Added |
| Duquesne Family Office | $104.0M | 2.39% | Unchanged |
| Castle Hook Partners | $46.5M | 0.50% | Added |
| Slate Path Capital | $10.8M | 0.15% | Unchanged |
| Tudor Investment | $2.7M | 0.01% | New |
Important information
Facts from public SEC filings, shown for information only. Not a recommendation. Not individualized investment advice. Gulfstream Capital and its clients may hold positions in securities shown.